Here is the link to the BIO-Europe Presentation. They forgot to fix the error on slide 15 (should be 7/16/2017 not 7/16/2016) and the PSA data on slide 18 is the same as we saw before at the October BIO Investor Forum slide deck. But slide 17 does have new data updated with a few more weeks of data. Interestingly, they've moved their "target" line from 36 weeks to 32 weeks. Of the 3 patients in Cohort 3, one had clinical progression and another had adverse event (anorexia/fatigue/nausea). Despite that, they have begun Cohort 4 with a couple of patients at that dose. Cohort 2 is still going strong!!!!!

BearDownAZ